Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
Back
Data-Driven Decision-Making in Advanced Breast Cancer: HER2 and HER2-low Breast Cancer Updates
Expert perspectives on the evolving treatment paradigm of HER2-expressing breast cancer and how learnings from recent clinical trials are impacting real-world practices.
Data-Driven Decision-Making in Advanced Breast Cancer: HER2 and HER2-low Breast Cancer Updates
Episodes
All
All
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5